In February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of my favorite stocks. Shares have jumped by more than 20,000% since then.

I believe we are about to do it again with this new AI project called Stargate

Matthew L. Trerotola net worth and biography

Matthew Trerotola Biography and Net Worth

CEO of Enovis

Matt Trerotola has spent most of his career in various roles at DuPont, Danaher Corporation, and McKinsey & Company. Prior to joining Enovis (Colfax at the time) where he served as a director of the Company since July 2015, Mr. Trerotola was an executive vice president at DuPont. At DuPont, he was responsible for $6.3 billion of revenue in safety and protection and electronic materials, along with overall corporate responsibility for Asia. At Danaher, he held several leadership positions from 2007 to 2013, including serving as Vice President and Group Executive for the $2.5 billion life sciences platform. Before that, he progressed from President of Videojet, a subsidiary of Danaher, to Group Executive for product identification. In these roles, he strengthened talent, greatly accelerated organic growth, improved profitability, and made strategic acquisitions. Mr. Trerotola received a Bachelor of Science degree in chemical engineering from the University of Virginia in 1989 and an MBA from Harvard Business School in 1995. Mr. Trerotola currently serves on the board of directors of AptarGroup, Inc. (NYSE: ATR).

What is Matthew L. Trerotola's net worth?: The estimated net worth of Matthew L. Trerotola is at least $9.15 million as of March 6th, 2023. Mr. Trerotola owns 197,388 shares of Enovis stock worth more than $9,154,855 as of November 17th. This net worth approximation does not reflect any other assets that Mr. Trerotola may own. Additionally, Mr. Trerotola receives a salary of $3,350,000.00 as CEO at Enovis. Learn More about Matthew L. Trerotola's net worth.
How old is Matthew L. Trerotola?: Mr. Trerotola is currently 57 years old. There are 7 older executives and no younger executives at Enovis. Learn More on Matthew L. Trerotola's age.
What is Matthew L. Trerotola's salary?: As the CEO of Enovis Co., Mr. Trerotola earns $3,350,000.00 per year. Learn More on Matthew L. Trerotola's salary.
How do I contact Matthew L. Trerotola?: The corporate mailing address for Mr. Trerotola and other Enovis executives is 2711 Centerville Road Suite 400, Wilmington DE, 19808. Enovis can also be reached via phone at 302-252-9160 and via email at [email protected]. Learn More on Matthew L. Trerotola's contact information.
Has Matthew L. Trerotola been buying or selling shares of Enovis?: Matthew L. Trerotola has not been actively trading shares of Enovis over the course of the past ninety days. Most recently, Matthew L. Trerotola sold 6,743 shares of the business's stock in a transaction on Monday, March 6th. The shares were sold at an average price of $57.69, for a transaction totalling $389,003.67. Following the completion of the sale, the chief executive officer now directly owns 197,388 shares of the company's stock, valued at $11,387,313.72. Learn More on Matthew L. Trerotola's trading history.
Who are Enovis' active insiders?: Enovis' insider roster includes Benjamin Berry (CFO), Christopher Hix (CFO), John Kleckner (Insider), Patricia Lang (SVP), A. Perfall (Director), Daniel Pryor (EVP), Brady Shirley (COO), Bradley Tandy (SVP), Matthew Trerotola (CEO), and Rajiv Vinnakota (Director). Learn More on Enovis' active insiders.

Matthew L. Trerotola Insider Trading History at Enovis

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/6/2023	Sell	6,743	$57.69	$389,003.67	197,388
2/27/2023	Sell	18,917	$56.21	$1,063,324.57	175,910
2/23/2023	Sell	3,945	$54.62	$215,475.90	162,544
2/21/2023	Sell	3,780	$62.11	$234,775.80	166,489

Matthew L. Trerotola Buying and Selling Activity at Enovis

Enovis Company Overview

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments. Its Prevention and Recovery segment offers orthopedic solutions and recovery sciences including rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators management, and physical therapy products which are used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals. The company's Reconstructive segment operates surgical implant business, which includes a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger, as well as surgical productivity tools. The company distributes its products through independent distributors and directly under the ESAB and DJO brands. Enovis Corporation was formerly known as Colfax Corporation. The company was founded in 1995 and is headquartered in Wilmington, Delaware.

Today's Range

Now: $46.38

$45.31

$46.61

50 Day Range

MA: $42.44

$38.72

$47.86

2 Week Range

Now: $46.38

$38.27

$65.03

Volume

467,649 shs

Average Volume

765,955 shs

Market Capitalization

$2.59 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.91

Bill Gates’s Next Big AI Bet: Stargate

From Brownstone Research | Ad